» Articles » PMID: 38354979

Personalized Drug Therapy: Innovative Concept Guided With Proteoformics

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Personalized medicine can reduce adverse effects, enhance drug efficacy, and optimize treatment outcomes, which represents the essence of personalized medicine in the pharmacy field. Protein drugs are crucial in the field of personalized drug therapy and are currently the mainstay, which possess higher target specificity and biological activity than small-molecule chemical drugs, making them efficient in regulating disease-related biological processes, and have significant potential in the development of personalized drugs. Currently, protein drugs are designed and developed for specific protein targets based on patient-specific protein data. However, due to the rapid development of two-dimensional gel electrophoresis and mass spectrometry, it is now widely recognized that a canonical protein actually includes multiple proteoforms, and the differences between these proteoforms will result in varying responses to drugs. The variation in the effects of different proteoforms can be significant and the impact can even alter the intended benefit of a drug, potentially making it harmful instead of lifesaving. As a result, we propose that protein drugs should shift from being targeted through the lens of protein (proteomics) to being targeted through the lens of proteoform (proteoformics). This will enable the development of personalized protein drugs that are better equipped to meet patients' specific needs and disease characteristics. With further development in the field of proteoformics, individualized drug therapy, especially personalized protein drugs aimed at proteoforms as a drug target, will improve the understanding of disease mechanisms, discovery of new drug targets and signaling pathways, provide a theoretical basis for the development of new drugs, aid doctors in conducting health risk assessments and making more cost-effective targeted prevention strategies conducted by artificial intelligence/machine learning, promote technological innovation, and provide more convenient treatment tailored to individualized patient profile, which will benefit the affected individuals and society at large.

Citing Articles

Multiomics as instrument to promote 3P medical approaches for the overall management of respiratory syncytial viral infections.

Bajinka O, Ouedraogo S, Li N, Zhan X EPMA J. 2025; 16(1):217-238.

PMID: 39991100 PMC: 11842696. DOI: 10.1007/s13167-024-00395-z.


Defining proteoform-specific interactions for drug targeting in a native cell signalling environment.

Lutomski C, Bennett J, El-Baba T, Wu D, Hinkle J, Burnap S Nat Chem. 2025; 17(2):204-214.

PMID: 39806141 PMC: 11794133. DOI: 10.1038/s41557-024-01711-w.


Tranexamic Acid as a Preventive Strategy Against Periprosthetic Joint Infection in Aseptic Revision Arthroplasty: A Comprehensive Review.

Sawant S, Deshpande S, Patil B, Wamborikar H, Jadawala V, Suneja A Cureus. 2024; 16(10):e70796.

PMID: 39493143 PMC: 11531398. DOI: 10.7759/cureus.70796.


Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review.

Jain R, Daigavane S Cureus. 2024; 16(9):e69895.

PMID: 39439625 PMC: 11494405. DOI: 10.7759/cureus.69895.


Editorial: Biomolecular modifications in endocrine-related cancers, volume II.

Zhan X, Li N, Grech G Front Endocrinol (Lausanne). 2024; 15:1485789.

PMID: 39415795 PMC: 11479951. DOI: 10.3389/fendo.2024.1485789.